A citation-based method for searching scientific literature

Ursula A Matulonis, Suzanne Berlin, Percy Ivy, Karin Tyburski, Carolyn Krasner, Corrine Zarwan, Anna Berkenblit, Susana Campos, Neil Horowitz, Stephen A Cannistra, Hang Lee, Julie Lee, Maria Roche, Margaret Hill, Christin Whalen, Laura Sullivan, Chau Tran, Benjamin D Humphreys, Richard T Penson. J Clin Oncol 2009
Times Cited: 200







List of co-cited articles
883 articles co-cited >1



Times Cited
  Times     Co-cited
Similarity


Incorporation of bevacizumab in the primary treatment of ovarian cancer.
Robert A Burger, Mark F Brady, Michael A Bookman, Gini F Fleming, Bradley J Monk, Helen Huang, Robert S Mannel, Howard D Homesley, Jeffrey Fowler, Benjamin E Greer,[...]. N Engl J Med 2011
54

OCEANS: a randomized, double-blind, placebo-controlled phase III trial of chemotherapy with or without bevacizumab in patients with platinum-sensitive recurrent epithelial ovarian, primary peritoneal, or fallopian tube cancer.
Carol Aghajanian, Stephanie V Blank, Barbara A Goff, Patricia L Judson, Michael G Teneriello, Amreen Husain, Mika A Sovak, Jing Yi, Lawrence R Nycum. J Clin Oncol 2012
781
53

Bevacizumab combined with chemotherapy for platinum-resistant recurrent ovarian cancer: The AURELIA open-label randomized phase III trial.
Eric Pujade-Lauraine, Felix Hilpert, Béatrice Weber, Alexander Reuss, Andres Poveda, Gunnar Kristensen, Roberto Sorio, Ignace Vergote, Petronella Witteveen, Aristotelis Bamias,[...]. J Clin Oncol 2014
766
48

A phase 3 trial of bevacizumab in ovarian cancer.
Timothy J Perren, Ann Marie Swart, Jacobus Pfisterer, Jonathan A Ledermann, Eric Pujade-Lauraine, Gunnar Kristensen, Mark S Carey, Philip Beale, Andrés Cervantes, Christian Kurzeder,[...]. N Engl J Med 2011
46

Combination cediranib and olaparib versus olaparib alone for women with recurrent platinum-sensitive ovarian cancer: a randomised phase 2 study.
Joyce F Liu, William T Barry, Michael Birrer, Jung-Min Lee, Ronald J Buckanovich, Gini F Fleming, Bj Rimel, Mary K Buss, Sreenivasa Nattam, Jean Hurteau,[...]. Lancet Oncol 2014
356
46

Olaparib maintenance therapy in platinum-sensitive relapsed ovarian cancer.
Jonathan Ledermann, Philipp Harter, Charlie Gourley, Michael Friedlander, Ignace Vergote, Gordon Rustin, Clare Scott, Werner Meier, Ronnie Shapira-Frommer, Tamar Safra,[...]. N Engl J Med 2012
38

Incorporation of pazopanib in maintenance therapy of ovarian cancer.
Andreas du Bois, Anne Floquet, Jae-Weon Kim, Joern Rau, Josep M del Campo, Michael Friedlander, Sandro Pignata, Keiichi Fujiwara, Ignace Vergote, Nicoletta Colombo,[...]. J Clin Oncol 2014
204
36

A Phase II, open-label study evaluating pazopanib in patients with recurrent ovarian cancer.
Michael Friedlander, Kenneth C Hancock, Danny Rischin, Mark J Messing, Claude A Stringer, Gemma M Matthys, Bo Ma, Jeffrey P Hodge, Joanne J Lager. Gynecol Oncol 2010
166
35

Olaparib in patients with recurrent high-grade serous or poorly differentiated ovarian carcinoma or triple-negative breast cancer: a phase 2, multicentre, open-label, non-randomised study.
Karen A Gelmon, Marc Tischkowitz, Helen Mackay, Kenneth Swenerton, André Robidoux, Katia Tonkin, Hal Hirte, David Huntsman, Mark Clemons, Blake Gilks,[...]. Lancet Oncol 2011
767
32


Randomized phase II placebo-controlled trial of maintenance therapy using the oral triple angiokinase inhibitor BIBF 1120 after chemotherapy for relapsed ovarian cancer.
Jonathan A Ledermann, Allan Hackshaw, Stan Kaye, Gordon Jayson, Hani Gabra, Iain McNeish, Helena Earl, Tim Perren, Martin Gore, Mojca Persic,[...]. J Clin Oncol 2011
153
31

Olaparib maintenance therapy in patients with platinum-sensitive relapsed serous ovarian cancer: a preplanned retrospective analysis of outcomes by BRCA status in a randomised phase 2 trial.
Jonathan Ledermann, Philipp Harter, Charlie Gourley, Michael Friedlander, Ignace Vergote, Gordon Rustin, Clare L Scott, Werner Meier, Ronnie Shapira-Frommer, Tamar Safra,[...]. Lancet Oncol 2014
850
31

Activity of sorafenib in recurrent ovarian cancer and primary peritoneal carcinomatosis: a gynecologic oncology group trial.
Daniela Matei, Michael W Sill, Heather A Lankes, Koen DeGeest, Robert E Bristow, David Mutch, S Diane Yamada, David Cohn, Valerie Calvert, John Farley,[...]. J Clin Oncol 2011
121
29

Phase II trial of bevacizumab in persistent or recurrent epithelial ovarian cancer or primary peritoneal cancer: a Gynecologic Oncology Group Study.
Robert A Burger, Michael W Sill, Bradley J Monk, Benjamin E Greer, Joel I Sorosky. J Clin Oncol 2007
569
28

Phase II, open-label, randomized, multicenter study comparing the efficacy and safety of olaparib, a poly (ADP-ribose) polymerase inhibitor, and pegylated liposomal doxorubicin in patients with BRCA1 or BRCA2 mutations and recurrent ovarian cancer.
Stan B Kaye, Jan Lubinski, Ursula Matulonis, Joo Ern Ang, Charlie Gourley, Beth Y Karlan, Amit Amnon, Katherine M Bell-McGuinn, Lee-May Chen, Michael Friedlander,[...]. J Clin Oncol 2012
328
27

Phase II study of bevacizumab in patients with platinum-resistant ovarian cancer or peritoneal serous cancer.
Stephen A Cannistra, Ursula A Matulonis, Richard T Penson, Julie Hambleton, Jakob Dupont, Howard Mackey, Jeffrey Douglas, Robert A Burger, Deborah Armstrong, Robert Wenham,[...]. J Clin Oncol 2007
536
26

Poly(ADP)-ribose polymerase inhibition: frequent durable responses in BRCA carrier ovarian cancer correlating with platinum-free interval.
Peter C Fong, Timothy A Yap, David S Boss, Craig P Carden, Marja Mergui-Roelvink, Charlie Gourley, Jacques De Greve, Jan Lubinski, Susan Shanley, Christina Messiou,[...]. J Clin Oncol 2010
639
26

Olaparib monotherapy in patients with advanced cancer and a germline BRCA1/2 mutation.
Bella Kaufman, Ronnie Shapira-Frommer, Rita K Schmutzler, M William Audeh, Michael Friedlander, Judith Balmaña, Gillian Mitchell, Georgeta Fried, Salomon M Stemmer, Ayala Hubert,[...]. J Clin Oncol 2015
998
26

Oral poly(ADP-ribose) polymerase inhibitor olaparib in patients with BRCA1 or BRCA2 mutations and recurrent ovarian cancer: a proof-of-concept trial.
M William Audeh, James Carmichael, Richard T Penson, Michael Friedlander, Bethan Powell, Katherine M Bell-McGuinn, Clare Scott, Jeffrey N Weitzel, Ana Oaknin, Niklas Loman,[...]. Lancet 2010
941
25

Targeting the DNA repair defect in BRCA mutant cells as a therapeutic strategy.
Hannah Farmer, Nuala McCabe, Christopher J Lord, Andrew N J Tutt, Damian A Johnson, Tobias B Richardson, Manuela Santarosa, Krystyna J Dillon, Ian Hickson, Charlotte Knights,[...]. Nature 2005
24

Inhibition of poly(ADP-ribose) polymerase in tumors from BRCA mutation carriers.
Peter C Fong, David S Boss, Timothy A Yap, Andrew Tutt, Peijun Wu, Marja Mergui-Roelvink, Peter Mortimer, Helen Swaisland, Alan Lau, Mark J O'Connor,[...]. N Engl J Med 2009
23

A phase 2 study of cediranib in recurrent or persistent ovarian, peritoneal or fallopian tube cancer: a trial of the Princess Margaret, Chicago and California Phase II Consortia.
H Hirte, S Lheureux, G F Fleming, A Sugimoto, R Morgan, J Biagi, L Wang, S McGill, S P Ivy, A M Oza. Gynecol Oncol 2015
37
62

A Phase 1 trial of the poly(ADP-ribose) polymerase inhibitor olaparib (AZD2281) in combination with the anti-angiogenic cediranib (AZD2171) in recurrent epithelial ovarian or triple-negative breast cancer.
Joyce F Liu, Sara M Tolaney, Michael Birrer, Gini F Fleming, Mary K Buss, Suzanne E Dahlberg, Hang Lee, Christin Whalen, Karin Tyburski, Eric Winer,[...]. Eur J Cancer 2013
109
21

A phase II study of sunitinib in patients with recurrent epithelial ovarian and primary peritoneal carcinoma: an NCIC Clinical Trials Group Study.
J J Biagi, A M Oza, H I Chalchal, R Grimshaw, S L Ellard, U Lee, H Hirte, J Sederias, S P Ivy, E A Eisenhauer. Ann Oncol 2011
89
22

Olaparib combined with chemotherapy for recurrent platinum-sensitive ovarian cancer: a randomised phase 2 trial.
Amit M Oza, David Cibula, Ana Oaknin Benzaquen, Christopher Poole, Ron H J Mathijssen, Gabe S Sonke, Nicoletta Colombo, Jiří Špaček, Peter Vuylsteke, Holger Hirte,[...]. Lancet Oncol 2015
339
20

Specific killing of BRCA2-deficient tumours with inhibitors of poly(ADP-ribose) polymerase.
Helen E Bryant, Niklas Schultz, Huw D Thomas, Kayan M Parker, Dan Flower, Elena Lopez, Suzanne Kyle, Mark Meuth, Nicola J Curtin, Thomas Helleday. Nature 2005
19



A phase II trial of Sunitinib malate in recurrent and refractory ovarian, fallopian tube and peritoneal carcinoma.
Susana M Campos, Richard T Penson, Ursula Matulonis, Neil S Horowitz, Christin Whalen, Lauren Pereira, Karin Tyburski, Maria Roche, Jackie Szymonifka, Suzanne Berlin. Gynecol Oncol 2013
30
56

Trapping of PARP1 and PARP2 by Clinical PARP Inhibitors.
Junko Murai, Shar-yin N Huang, Benu Brata Das, Amelie Renaud, Yiping Zhang, James H Doroshow, Jiuping Ji, Shunichi Takeda, Yves Pommier. Cancer Res 2012
981
17

AZD2171: a highly potent, orally bioavailable, vascular endothelial growth factor receptor-2 tyrosine kinase inhibitor for the treatment of cancer.
Stephen R Wedge, Jane Kendrew, Laurent F Hennequin, Paula J Valentine, Simon T Barry, Sandra R Brave, Neil R Smith, Neil H James, Michael Dukes, Jon O Curwen,[...]. Cancer Res 2005
566
16

The poly(ADP-ribose) polymerase inhibitor niraparib (MK4827) in BRCA mutation carriers and patients with sporadic cancer: a phase 1 dose-escalation trial.
Shahneen K Sandhu, William R Schelman, George Wilding, Victor Moreno, Richard D Baird, Susana Miranda, Lucy Hylands, Ruth Riisnaes, Martin Forster, Aurelius Omlin,[...]. Lancet Oncol 2013
351
16

Anti-angiopoietin therapy with trebananib for recurrent ovarian cancer (TRINOVA-1): a randomised, multicentre, double-blind, placebo-controlled phase 3 trial.
Bradley J Monk, Andrés Poveda, Ignace Vergote, Francesco Raspagliesi, Keiichi Fujiwara, Duk-Soo Bae, Ana Oaknin, Isabelle Ray-Coquard, Diane M Provencher, Beth Y Karlan,[...]. Lancet Oncol 2014
187
16

Rucaparib in relapsed, platinum-sensitive high-grade ovarian carcinoma (ARIEL2 Part 1): an international, multicentre, open-label, phase 2 trial.
Elizabeth M Swisher, Kevin K Lin, Amit M Oza, Clare L Scott, Heidi Giordano, James Sun, Gottfried E Konecny, Robert L Coleman, Anna V Tinker, David M O'Malley,[...]. Lancet Oncol 2017
554
16

Niraparib Maintenance Therapy in Platinum-Sensitive, Recurrent Ovarian Cancer.
Mansoor R Mirza, Bradley J Monk, Jørn Herrstedt, Amit M Oza, Sven Mahner, Andrés Redondo, Michel Fabbro, Jonathan A Ledermann, Domenica Lorusso, Ignace Vergote,[...]. N Engl J Med 2016
16

Intravenous aflibercept for treatment of recurrent symptomatic malignant ascites in patients with advanced ovarian cancer: a phase 2, randomised, double-blind, placebo-controlled study.
Walter H Gotlieb, Frederic Amant, Suresh Advani, Chanchal Goswami, Hal Hirte, Diane Provencher, Naresh Somani, S Diane Yamada, Jean-Francois Tamby, Ignace Vergote. Lancet Oncol 2012
97
15

Initial toxicity assessment of ICON6: a randomised trial of cediranib plus chemotherapy in platinum-sensitive relapsed ovarian cancer.
F A Raja, C L Griffin, W Qian, H Hirte, M K Parmar, A M Swart, J A Ledermann. Br J Cancer 2011
39
38

Cediranib in patients with relapsed platinum-sensitive ovarian cancer (ICON6): a randomised, double-blind, placebo-controlled phase 3 trial.
Jonathan A Ledermann, Andrew C Embleton, Fharat Raja, Timothy J Perren, Gordon C Jayson, Gordon J S Rustin, Stan B Kaye, Hal Hirte, Elizabeth Eisenhauer, Michelle Vaughan,[...]. Lancet 2016
129
15

A randomized phase II trial of maintenance therapy with Sorafenib in front-line ovarian carcinoma.
Thomas J Herzog, Giovanni Scambia, Byoung-Gie Kim, Catherine Lhommé, Janina Markowska, Isabelle Ray-Coquard, Jalid Sehouli, Nicoletta Colombo, Minghua Shan, Oana Petrenciuc,[...]. Gynecol Oncol 2013
56
25

Ovarian cancer.
Gordon C Jayson, Elise C Kohn, Henry C Kitchener, Jonathan A Ledermann. Lancet 2014
969
14

Sorafenib in combination with gemcitabine in recurrent epithelial ovarian cancer: a study of the Princess Margaret Hospital Phase II Consortium.
Stephen A Welch, Hal W Hirte, Laurie Elit, Russel J Schilder, Lisa Wang, Katrina Macalpine, John J Wright, Amit M Oza. Int J Gynecol Cancer 2010
42
30

Randomized, double-blind, placebo-controlled phase II study of AMG 386 combined with weekly paclitaxel in patients with recurrent ovarian cancer.
Beth Y Karlan, Amit M Oza, Gary E Richardson, Diane M Provencher, Vincent L Hansen, Martin Buck, Setsuko K Chambers, Prafull Ghatage, Charles H Pippitt, John V Brown,[...]. J Clin Oncol 2012
154
13

Germline and somatic mutations in homologous recombination genes predict platinum response and survival in ovarian, fallopian tube, and peritoneal carcinomas.
Kathryn P Pennington, Tom Walsh, Maria I Harrell, Ming K Lee, Christopher C Pennil, Mara H Rendi, Anne Thornton, Barbara M Norquist, Silvia Casadei, Alexander S Nord,[...]. Clin Cancer Res 2014
496
13

Pazopanib plus weekly paclitaxel versus weekly paclitaxel alone for platinum-resistant or platinum-refractory advanced ovarian cancer (MITO 11): a randomised, open-label, phase 2 trial.
Sandro Pignata, Domenica Lorusso, Giovanni Scambia, Daniela Sambataro, Stefano Tamberi, Saverio Cinieri, Anna M Mosconi, Michele Orditura, Alba A Brandes, Valentina Arcangeli,[...]. Lancet Oncol 2015
86
15


Phase III trial of carboplatin and paclitaxel compared with cisplatin and paclitaxel in patients with optimally resected stage III ovarian cancer: a Gynecologic Oncology Group study.
Robert F Ozols, Brian N Bundy, Benjamin E Greer, Jeffrey M Fowler, Daniel Clarke-Pearson, Robert A Burger, Robert S Mannel, Koen DeGeest, Ellen M Hartenbach, Rebecca Baergen. J Clin Oncol 2003
12

Paclitaxel plus platinum-based chemotherapy versus conventional platinum-based chemotherapy in women with relapsed ovarian cancer: the ICON4/AGO-OVAR-2.2 trial.
M K B Parmar, J A Ledermann, N Colombo, A du Bois, J-F Delaloye, G B Kristensen, S Wheeler, A M Swart, W Qian, V Torri,[...]. Lancet 2003
788
12

Hypoxia-induced down-regulation of BRCA1 expression by E2Fs.
Ranjit S Bindra, Shannon L Gibson, Alice Meng, Ulrica Westermark, Maria Jasin, Andrew J Pierce, Robert G Bristow, Marie K Classon, Peter M Glazer. Cancer Res 2005
225
12

Mechanisms of resistance to therapies targeting BRCA-mutant cancers.
Christopher J Lord, Alan Ashworth. Nat Med 2013
266
12

Safety and Antitumor Activity of Anti-PD-1 Antibody, Nivolumab, in Patients With Platinum-Resistant Ovarian Cancer.
Junzo Hamanishi, Masaki Mandai, Takafumi Ikeda, Manabu Minami, Atsushi Kawaguchi, Toshinori Murayama, Masashi Kanai, Yukiko Mori, Shigemi Matsumoto, Shunsuke Chikuma,[...]. J Clin Oncol 2015
606
12


Co-cited is the co-citation frequency, indicating how many articles cite the article together with the query article. Similarity is the co-citation as percentage of the times cited of the query article or the article in the search results, whichever is the lowest. These numbers are calculated for the last 100 citations when articles are cited more than 100 times.